Name | PKC-IN-4 |
---|
Description | PKC-IN-4 (compound 7l) is a potent and orally active aPKC inhibitor with an IC50 of 0.52 µM. PKC-IN-4 inhibits TNF-α induced NF-κB activity in vitro. PKC-IN-4 blocks VEGF- and TNFα-induced permeability across the retinal vasculature[1]. |
---|---|
Related Catalog | |
Target |
PKC:0.52 μM (IC50) |
In Vitro | PKC-IN-4 (compound 7l) shows VEGF - induced endothelial permeability with an EC50 of 0.071 µM[1]. |
In Vivo | PKC-IN-4 (10 mg/kg for i.v.; 20 mg/kg for p.o.) shows orally active with oral bioavailability of 81.7%[1]. Animal Model: Animal Model: CD-1 mice[1] Dosage: 10, 20 mg/kg Administration: 10 mg/kg for i.v.; 20 mg/kg for p.o. Result: Showed good PK parameters with oral bioavailability of 81.7%. |
References |
Molecular Formula | C21H25N5S |
---|---|
Molecular Weight | 379.52 |